Burris H A
Oncology Service, Brooke Army Medical Center Fort Sam Houston, Texas, USA.
Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):50-2.
The results from preclinical studies using murine tumor models show that the combination of docetaxel (Taxotere) and fluorouracil (5-FU) is highly synergistic. Phase I studies in patients with advanced solid tumors indicate that 60 mg/m2 of docetaxel administered as a 1-hour intravenous infusion followed by a daily intravenous bolus of 300 mg/m2 of 5-FU on days 1 through 5 is the recommended dose for phase II studies. Preliminary results from another phase I study using a continuous infusion regimen for 5-FU suggest that 85 mg/m2 of docetaxel administered as a 1-hour intravenous infusion followed by continuous infusion of 750 mg/m2 per day of 5-FU on days 1 through 5 may be the recommended dose for phase II studies. As expected, dose-limiting toxicities included neutropenia and mucositis. Ongoing phase I/II and II studies are investigating the combination of docetaxel with continuous infusion of 5-FU in patients with metastatic breast cancer and with cisplatin (Platinol) and continuous infusion of 5-FU, with and without leucovorin, in patients with head and neck cancer. Preliminary results are encouraging and warrant further study.
使用小鼠肿瘤模型的临床前研究结果表明，多西他赛（泰索帝）和氟尿嘧啶（5-FU）联合使用具有高度协同作用。针对晚期实体瘤患者的I期研究表明，多西他赛60mg/m²以1小时静脉输注给药，随后在第1至5天每日静脉推注300mg/m²的5-FU，是II期研究的推荐剂量。另一项使用5-FU持续输注方案的I期研究的初步结果表明，多西他赛85mg/m²以1小时静脉输注给药，随后在第1至5天持续输注每日750mg/m²的5-FU，可能是II期研究的推荐剂量。正如预期的那样，剂量限制性毒性包括中性粒细胞减少和粘膜炎。正在进行的I/II期和II期研究正在调查多西他赛与5-FU持续输注联合用于转移性乳腺癌患者，以及与顺铂（铂尔定）和5-FU持续输注联合使用（加或不加亚叶酸）用于头颈癌患者的情况。初步结果令人鼓舞，值得进一步研究。
